FDA's Bioresearch Monitoring program evaluates whether clinical data submitted to the Agency were generated under adequate controls — covering sponsors, monitors, CROs, investigators and IRBs. For a sponsor, BIMO expectations are best treated as the design specification for the clinical quality system, not as an inspection exercise.
Sponsor responsibility does not transfer
Delegating monitoring, data management or safety reporting to a CRO transfers the activity, not the responsibility. The evidence that a sponsor exercised oversight — reviewed monitoring reports, escalated issues, tracked corrective actions — is what supports the data.
What the record needs to show
- Defined delegation, in writing, with the sponsor's oversight activities specified
- Monitoring findings trended and escalated rather than closed site by site
- Protocol deviations classified consistently and analyzed for systemic cause
- Data corrections traceable to source with reasons recorded
- Safety reporting timelines met and demonstrable
Build it early
Clinical quality systems assembled during a submission review are visible as such. The oversight record has to be created contemporaneously — it is not something that can be reconstructed once the study has closed.
Reviewed by the named consultant. Last updated July 14, 2026. General information only — not regulatory or legal advice for a specific situation.